Trial Profile
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Aug 2022
Price :
$35
*
At a glance
- Drugs Alpha fetoprotein targeted T cell therapy Adaptimmune (Primary) ; Cyclophosphamide; Fludarabine
- Indications Carcinoma; Liver cancer
- Focus Adverse reactions; First in man
- Acronyms ADP-A2AFP
- Sponsors Adaptimmune
- 26 Aug 2022 Planned End Date changed from 1 Jun 2026 to 7 Jul 2036.
- 26 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 05 Sep 2021 According to an Adaptimmune media release, Dose escalation is complete, and this trial is intended to treat up to 25 patients with doses up to 10 billion transduced cells in the expansion phase.